GlassScriptPhysician profile
Bradley M Haverkos
NPI 1679707319
$120,386.49
in general payments reported to CMS, 2019-2025
25 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $13K · 2021: $10K · 2022: $37K · 2023: $6,339 · 2024: $13K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Honoraria: $3,750 · Travel and Lodging: $2,938 · Food and Beverage: $1,918 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,107.82 |
| Honoraria | $3,750.00 |
| Travel and Lodging | $2,938.43 |
| Food and Beverage | $1,918.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $407.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $38,750.33 | 2019-2025 | Poteligeo |
| Adc Therapeutics America, INC. | $24,061.13 | 2022-2024 | |
| Acrotech Biopharma INC. | $17,036.99 | 2022-2025 | Beleodaq |
| Seagen INC. | $11,690.81 | 2019-2023 | |
| Genentech, INC. | $6,260.17 | 2023 | Polivy |
| Pierre Fabre Pharmaceuticals, INC. | $4,886.17 | 2025 | |
| Gilead Sciences, INC. | $4,750.18 | 2019-2020 | |
| Verastem, INC. | $4,183.65 | 2019-2020 | |
| Aurobindo Pharma USA, INC. | $2,319.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $2,031.25 | 2021 | |
| Incyte Corporation | $1,877.51 | 2020-2024 | Jakafi, Pemazyre |
| Karyopharm Therapeutics INC. | $1,070.17 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $500.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $244.57 | 2025 | |
| Spectrum Pharmaceuticals INC. | $201.34 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $163.04 | 2025 | |
| Kite Pharma, INC. | $130.37 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $125.00 | 2019 | |
| Adaptive Biotechnologies Corporation | $45.26 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $25.81 | 2025 | Valchlor |
| Abbvie INC. | $16.70 | 2025 | |
| Terumo Bct, INC. | $16.29 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Haverkos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.